The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B

• Main Authors: Solomon M., Schechter M., Liu A., McManhan V., Guanira J., Hance R., Chariyalertsak S., Mayer K., Grant R., Bekker L., Buchbinder S., Casapia M., Kallas E., Lama J., Montoya O., Veloso V.
• 格式: 雜誌
• 出版: 2017
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84959166158&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/42660

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. Background: Pre-exposure prophylaxis (PrEP) with daily oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) prevents HIV infection. The safety and feasibility of HIV PrEP in the setting of hepatitis B virus (HBV) infection w...